In all eukaryotes, the target of rapamycin (TOR) signalling pathway couples energy and
nutrient abundance to the execution of cell growth and division, owing to the ability of TOR …

Mammalian target of rapamycin (mTOR) is a PI3K-related kinase that regulates cell growth,
proliferation, and survival via mTOR complex 1 (mTORC1) and mTORC2. The mTOR …

Molecular-targeted agents are increasingly used for the treatment of cancer. However, the
attrition rate for drugs that enter early clinical trials is higher than for other branches of …

The mechanistic target of rapamycin (mTOR), via its two distinct multiprotein complexes,
mTORC1, and mTORC2, plays a central role in the regulation of cellular growth, metabolism …

Effectively treating patients with multiple myeloma is challenging. The development of
therapeutic regimens over the past decade that incorporate the proteasome inhibitor …

Mammalian target of rapamycin (mTOR) is a central controller of cell growth, proliferation,
metabolism and angiogenesis. mTOR signaling is often dysregulated in various human …

The mammalian target of rapamycin (mTOR) has emerged as a potential target for drug
development, particularly due to the fact that it plays such a crucial role in cancer biology. In …

Proteasome inhibition with bortezomib is a validated approach to the treatment of multiple
myeloma, but drug resistance often emerges and limits its utility in the retreatment setting. To …

Abstract The PI3K-Akt pathway is a vital regulator of cell proliferation and survival.
Alterations in the PIK3CA gene that lead to enhanced PI3K kinase activity have been …

Purpose: The growth and survival of acute myeloid leukemia (AML) cells are enhanced by
the deregulation of signaling pathways such as phosphoinositide 3-kinase (PI3K)/Akt and …